GEROPHARM is a pharmaceutical company that emphasizes a comprehensive approach to drug development, particularly in the fields of endocrinology, neurology, psychiatry, ophthalmology, and gynecology. The company operates a full-cycle research and development center located in a Special Economic Zone in St. Petersburg, where it adheres to Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP) standards. This facility is dedicated to the biotech development of drugs, with a specific focus on producing biosimilars of insulin. GEROPHARM's production capabilities are designed to meet the entire lifecycle of medicinal products, from initial molecule development to the final registration of the drug.

In addition to its domestic operations, GEROPHARM has expanded its reach internationally, particularly in Venezuela, where it has established a partnership to produce insulin locally. This collaboration involves transferring technology and expertise to a Venezuelan manufacturing site, which is expected to produce over 3 million insulin vials annually. The company has already shipped significant quantities of insulin to Venezuela, addressing critical shortages in the country. GEROPHARM is also committed to enhancing diabetes care through training programs for healthcare professionals and establishing diabetes education centers, thereby contributing to the overall improvement of the pharmaceutical landscape in Venezuela.

Russia

GEROPHARM is one of the 20 leading Russian manufacturers of pharmaceutical preparations. The company has modern industrial sites, where production is carried out on the principle of Full-Cycle: from production of active pharmaceutical ingredients to a market release of the finished product. In addition to the drug production, the company conducts independent studies, annually makes considerable investment in R&D. 

GEROPHARM

Company Details